Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Nature Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
Nat. Med. 2023 Aug 17;[EPub Ahead of Print], Y Lin, NS Raje, JG Berdeja, DS Siegel, S Jagannath, D Madduri, M Liedtke, J Rosenblatt, MV Maus, M Massaro, F Petrocca, A Yeri, O Finney, A Caia, Z Yang, N Martin, TB Campbell, J Rytlewski, J Fuller, K Hege, NC Munshi, JN KochenderferFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.